Shares of Aurinia Pharmaceuticals (AUPH) are soaring 7.40% in pre-market trading on Thursday following the company's release of impressive second-quarter financial results and an upward revision of its full-year guidance. The biotech firm, which specializes in developing therapies for severe autoimmune diseases, has surpassed analyst expectations with its Q2 performance.

Aurinia reported earnings per share of $0.16 for Q2 2025, significantly beating the FactSet consensus estimate of $0.13. This represents a substantial improvement from $0.01 per share in the same quarter last year. The company's total revenue for the quarter reached $70.0 million, up 22% year-over-year and surpassing analyst projections of $63.8 million. Notably, net product sales of LUPKYNIS, Aurinia's FDA-approved oral therapy for lupus nephritis, grew to $66.6 million, marking a 21% increase from the previous year.

Adding to the positive sentiment, Aurinia has raised its full-year 2025 guidance. The company now expects total revenue in the range of $260 million to $270 million, up from its previous forecast of $250 million to $260 million. This upward revision, coupled with the strong quarterly performance, has bolstered investor confidence in Aurinia's growth trajectory and the commercial success of its key product, LUPKYNIS. The company's improved financial outlook and robust product sales suggest a promising future for Aurinia in the competitive biotech landscape.